Who
W. Michael Flanagan
Director
Company insider
Files Form 4 as: Director, Atrium Therapeutics; Chief Scientific Officer, Avidity Biosciences.
In numbers
- Trades disclosed
- 69
- Buys
- 0
- Sells
- 14
- Bought
- $0
- Sold
- $14.1M
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 21 Jan 2021
- Last trade
- 18 Sep 2026
- Last filed
- 22 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 18 Sep 2026filed 22 Sep 2026 | RNA Atrium TherapeuticsBiotechnology | SEC FORM 4 Code F | $204K22,812 at $8.95 | filing |
| 18 Sep 2026filed 22 Sep 2026 | RNA Atrium TherapeuticsBiotechnology | SEC FORM 4 Code F | $204K22,812 at $8.95 | filing |
| 27 Feb 2026filed 2 Mar 2026 | RNA Atrium Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 27 Feb 2026filed 2 Mar 2026 | RNA Atrium Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 27 Feb 2026filed 27 Feb 2026 | Avidity BiosciencesBiotechnology | SEC FORM 4 Code D | —150,365 | filing |
| 27 Feb 2026filed 27 Feb 2026 | Avidity Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —25,000 | filing |
| 27 Feb 2026filed 27 Feb 2026 | Avidity Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —66,500 | filing |
| 27 Feb 2026filed 27 Feb 2026 | Avidity Biosciencesoption or derivative | SEC FORM 4 Code D | —25,000 | filing |
| 27 Feb 2026filed 27 Feb 2026 | Avidity Biosciencesoption or derivative | SEC FORM 4 Code D | —66,500 | filing |
| 27 Feb 2026filed 27 Feb 2026 | Avidity Biosciencesoption or derivative | SEC FORM 4 Code D | —96,000 | filing |
| 27 Feb 2026filed 27 Feb 2026 | Avidity Biosciencesoption or derivative | SEC FORM 4 Code D | —72,000 | filing |
| 27 Feb 2026filed 27 Feb 2026 | Avidity Biosciencesoption or derivative | SEC FORM 4 Code D | —88,000 | filing |
| 27 Feb 2026filed 27 Feb 2026 | Avidity Biosciencesoption or derivative | SEC FORM 4 Code D | —50,000 | filing |
| 27 Feb 2026filed 27 Feb 2026 | Avidity Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —96,000 | filing |
| 27 Feb 2026filed 27 Feb 2026 | Avidity Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —72,000 | filing |
| 27 Feb 2026filed 27 Feb 2026 | Avidity Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —88,000 | filing |
| 27 Feb 2026filed 27 Feb 2026 | Avidity Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —50,000 | filing |
| 27 Feb 2026filed 27 Feb 2026 | Avidity Biosciences | SEC FORM 4 Code D | —150,365 | filing |
| 21 Jan 2026filed 23 Jan 2026 | Avidity BiosciencesBiotechnology | SEC FORM 4 Sold | $288K3,976 at $72.45 | filing |
| 21 Jan 2026filed 23 Jan 2026 | Avidity BiosciencesBiotechnology | SEC FORM 4 Sold | $185K2,558 at $72.45 | filing |
News
No headline names them, or the companies they trade most, lately.